Administering brain tumour patients genetically modified poliovirus therapy can boost their three-year survival rate by 21 per cent show results of a clinical trial. Comparatively the previously available standard treatment could save just 4 per cent of patients with glioblastoma -- a malignant tumour affecting the brain or spine the researchers said. Glioblastoma remains a lethal and devastating disease despite advances in surgical and radiation therapies as well as new chemotherapy and targeted agents said Darell D. Bigner from the Duke University in North Carolina US. With the survival rates in this early phase of the poliovirus therapy we are
